Novartis AG
NVSEF
$121.91
-$4.88-3.85%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.02% | 11.30% | 10.73% | 8.96% | 9.80% |
| Total Other Revenue | 46.35% | 18.94% | 15.16% | 7.64% | 6.14% |
| Total Revenue | 12.95% | 11.50% | 10.85% | 8.92% | 9.70% |
| Cost of Revenue | 9.55% | 6.82% | 6.69% | -1.03% | -0.06% |
| Gross Profit | 14.05% | 13.09% | 12.29% | 12.53% | 13.28% |
| SG&A Expenses | 5.57% | 2.76% | 0.60% | 2.24% | 3.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -40.67% | 84.51% | 79.86% | 143.72% | 390.85% |
| Total Operating Expenses | 7.92% | 6.66% | 5.73% | -6.48% | 3.08% |
| Operating Income | 24.18% | 23.13% | 24.51% | 54.75% | 28.08% |
| Income Before Tax | 43.21% | 53.29% | 49.51% | 53.12% | 30.53% |
| Income Tax Expenses | 142.01% | 230.87% | 208.71% | -8.54% | -36.60% |
| Earnings from Continuing Operations | 35.23% | 41.16% | 39.28% | 62.19% | 42.73% |
| Earnings from Discontinued Operations | -- | -- | -- | 888.49% | 939.59% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 900.00% | 66.67% | 150.00% | 200.00% | 50.00% |
| Net Income | -15.59% | -15.65% | -19.59% | 124.64% | 111.49% |
| EBIT | 24.18% | 23.13% | 24.51% | 54.75% | 28.08% |
| EBITDA | 12.96% | 10.49% | 9.20% | 34.37% | 17.23% |
| EPS Basic | -12.56% | -13.28% | -17.72% | 130.92% | 118.87% |
| Normalized Basic EPS | 28.97% | 27.60% | 27.11% | 62.56% | 33.82% |
| EPS Diluted | -12.68% | -13.39% | -17.71% | 130.18% | 118.38% |
| Normalized Diluted EPS | 28.95% | 27.55% | 27.02% | 62.65% | 33.92% |
| Average Basic Shares Outstanding | -3.35% | -2.90% | -2.76% | -3.01% | -3.62% |
| Average Diluted Shares Outstanding | -3.30% | -2.83% | -2.66% | -3.01% | -3.64% |
| Dividend Per Share | -1.44% | -1.44% | -1.44% | 13.24% | 13.24% |
| Payout Ratio | 0.21% | 0.76% | 0.31% | -0.53% | -0.50% |